The device was designed to treat patients facing a heightened risk of recurrent stroke.
Overall, mitral valve surgery after TEER was associated with a 30-day mortality rate of 16.6% and one-year mortality rate of 31.3%.
Recent research published in JAMA Cardiology caught the agency's attention.
The next-generation devices were designed to be used without blood-thinners.
The study's authors examined data from men and women who underwent TEER with the MitraClip device in addition to guideline-directed medical therapy.
CardioSmart, an online resource for both patients and clinicians, has a new editor.
Innovate Healthcare thanks our partners for supporting our newsletters.Sponsorship has no influence on editorial content.Interested in reaching our audiences, contact our team*|LIST:ADDRESSLINE|*You received this email because you signed up for newsletters from Innovate Healthcare.Change your preferences or unsubscribe hereContact Us | Unsubscribe from all | Privacy Policy© Innovate Healthcare, a TriMed Media brand
